S645C Point Mutation Suppresses Degradation of EGFR to Promote Progression of Glioblastoma.

Huang, Wenda; Zou, Ling; Hao, Zhaonian; Wang, Baofeng; Mao, Feng; Duan, Qiuhong; Guo, Dongsheng

Huang, Wenda; Zou, Ling; Hao, Zhaonian; Wang, Baofeng; Mao, Feng; Duan, Qiuhong; Guo, Dongsheng.

Afiliação

Huang W; Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zou L; Department of Biochemistry and Molecular Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hao Z; Department of Neurosurgery, Beijing TianTan Hospital, Capital Medical University, Beijing, China.
Wang B; Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Mao F; Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Duan Q; Department of Biochemistry and Molecular Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Guo D; Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Front Oncol ; 12: 904383, 2022.

Article em En | MEDLINE | ID: mdl-35814475

Palavras-chave

EGFR; EGFR degradation; S645C point mutation; glioblastoma; individualized treatment; targeted therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google